Azamacrocyclic metal complexes as CXCR4 antagonists

The chemokine receptor CXCR4 is a member of the seven transmembrane GPCR family, which is implicated in multiple diseases, including HIV infection, cancers, and rheumatoid arthritis. Low-molecular-weight nonpeptidic compounds, including AMD3100 and various pyridyl macrocyclic zinc(II) complexes, have been identified as selective antagonists of CXCR4. In the present study, structure-activity relationship studies were performed by combining the common structural features of alkylamino and pyridiyl macrocyclic antagonists. Several new zinc(II) or copper(II) complexes demonstrated potent anti-HIV activity, strong CXCR4-binding activity, and significant inhibitory activity against Ca(2+) mobilization induced by CXCL12 stimulation. These results may prove useful in the design of novel CXCR4 antagonists, and the compounds described could potentially be developed as therapeutics against CXCR4-relevant diseases or chemical probes to study the biological activity of CXCR4.     

Imidazolidinones and Imidazolidine-2,4-diones as Antiviral Agents

Imidazolidinones and imidazolidine-2,4-diones are important classes of heterocyclic compounds that possess potent activities against several viruses such as dengue virus, enterovirus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The first imidazolidinone derivative as an anti-HIV agent was reported in 1996. Imidazolidinones inhibit HIV aspartic protease activity, and also act as CCR5 co-receptor antagonists. Significant effort has been devoted to the design of various imidazolidinone analogues that are active against drug-resistant HIV strains, with fewer side effects. Different scaffolds have been designed through both rational drug design strategies and computer-aided drug design. Imidazolidinones have been found to be potent against HIV, and preclinical studies are currently in progress. There are some reports of imidazolidinones as having both anti-HCV and anti-dengue virus activity, and more research has yet to be done along these lines. These compounds inhibit NS3 serine protease of HCV, and NS2B-NS3 protease of dengue virus. Pyridyl-imidazolidinones possess very specific and potent activity against human enterovirus 71 (EV71) by targeting the EV71 capsid protein VP1, and inhibiting viral adsorption and/or viral RNA uncoating.     

Synthesis and Antiviral Evaluation of 3′-Fluoro-4′-modified-5′-norcarbocyclic Nucleoside Phosphonates

The synthesis and anti-HIV evaluation of hitherto unknown 3′-fluoro-5′-norcarbocyclic nucleoside phosphonates bearing adenine with modifications at the 4′ position (ethynyl, vinyl, ethyl, hydroxymethyl) is described. One of the synthesized compounds was found to be an inhibitor of HIV-1 replication, but with moderate efficiency relative to (R)-9-(2-phosphonylmethoxypropyl)adenine ((R)-PMPA, tenofovir), with no concomitant cytotoxicity.     

非核苷逆转录酶抑制剂新进展

治疗艾滋病的逆转录酶抑制剂主要包括核苷逆转录酶抑制剂(NRTIs,如齐多夫定)和非核苷逆转录酶抑制剂(NNRTIs,如奈韦拉平)。目前至少有30多类非核苷类化合物被发现具有选择性抑制HIV-1逆转录酶的作用,其中已经获得美国FDA批准上市的包括奈韦拉平、地拉夫定和埃法韦伦,还有一些品种正在进行临床试验,其中效果较好的包括MKC-442、trovirdine、loviride等。“第一代”NNRTIs的缺点是容易使病毒产生变异,出现耐药性。“第二代”NNRTIs则活性谱广,不容易产生耐药的变异病毒。属于“第二代”NNRTIs的化合物除了埃法韦伦外,还包括埃法韦伦的衍生物DPC083,咪唑衍生物capravirine,二芳基嘧啶类化合物etravirine、rilpivirine。此外,还有一些喹喔啉、吡嗪酮类、烯基二芳基甲烷等也表现出很好的抗HIV活性。相信在不久的将来,将有更多更有效的非核苷逆转录酶抑制剂为人类的健康带来福音。     

Glu659Leu substitution of recombinant HIV fusion inhibitor C52L induces soluble expression in Escherichia coli with equivalent anti-HIV potency

The C-peptides used to prevent HIV infection, such as T20 and C34, are chemically synthesized, making them costly drugs. The sensitivity of peptides to protease also restricts their clinical application. We showed previously that C52L, a recombinant peptide produced in bacteria, is a potent anti-HIV C-peptide, although most of the peptide accumulates in inclusion bodies. Here we applied leucine and glutamine scanning mutagenesis to the heptad-repeat of C52L to produce an optimized variant of C52L that is potent and soluble when expressed in bacteria. We present that the substitution of Asn656 and Glu659 with leucine (peptide L14 and L15, respectively) can increase the helical content of this peptide. These substitutions also result in soluble expression. We measured the inhibitory activities of these mutant peptides against laboratory-adapted HIV-1 strains and found that L15 and its parental peptide C52L have equivalent anti-HIV activities. Moreover, L15 was found to be more stable to proteinase K digestion than C52L. Thus, we show that the L15 peptide can be expressed in a soluble state and exhibits potent anti-HIV activity. This peptide may be further developed as an anti-HIV therapeutic and/or microbicide for the prevention of HIV sexual transmission.     

Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4

The HIV coreceptor CCR5 is a validated target for both the prevention and therapy of HIV infection. PSC-RANTES, an N-terminally modified analogue of one of the natural chemokine ligands of CCR5 (RANTES/CCL5), is a potent inhibitor of HIV entry into target cells. Here, we set out to engineer the anti-HIV activity of PSC-RANTES into another natural CCR5 ligand (MIP-1beta/CCL4), by grafting into it the key N-terminal pharmacophore region from PSC-RANTES. We were able to identify MIP-1beta/CCL4 analogues that retain the receptor binding profile of MIP-1beta/CCL4, but acquire the very high anti-HIV potency and characteristic inhibitory mechanism of PSC-RANTES. Unexpectedly, we discovered that in addition to N-terminal structures from PSC-RANTES, the side chain of Lys33 is also necessary for full anti-HIV potency.     

Novel Peptidyl Aryl Vinyl Sulfones as Highly Potent and Selective Inhibitors of Cathepsins L and B

Herein we present the design, synthesis, and evaluation of a structurally novel library of 20 peptidyl 3‐aryl vinyl sulfones as inhibitors of cathepsins L and B. The building blocks, described here for the first time, were synthesized in a highly efficient and enantioselective manner, starting from 3‐aryl‐substituted allyl alcohols. The corresponding vinyl sulfones were prepared by a new approach, based on a combination of solid‐phase peptide synthesis using the Fmoc/tBu strategy, followed by solution‐phase coupling to the corresponding (R)‐3‐amino‐3‐aryl vinyl sulfones as trifluoroacetate salts. The inhibitory activity of the resulting compounds against cathepsins L and B was evaluated, and the compound exhibiting the best activity was selected for enzymatic characterization. Finally, docking studies were performed in order to identify key structural features of the aryl substituent.     

三嗪类光生酸剂的产酸性能研究

采用UV-vis光谱分析的方法,选用罗丹明B为酸示踪剂,对4种新合成的三嗪类光生酸剂(PAG1 -PAG4),分别在405nm和365nm下乙腈中的分解及产酸性能进行了研究,推导计算得到了其分解及产酸量子产率,并对这4种化合物的产酸量子产率进行了比较。实验结果表明405nm光源下4种三嗪光生酸剂中2-(9-葸乙烯基)-4,6-双(三氯甲基)-1,3,5-三嗪(PAG4)的分解和产酸量子产率达到分别为10%,9%,为四者中最高的;2-(4-羟基-1-苯乙烯基)-4,6-双(三氯甲基)-1,3,5-三嗪(PAG2)几乎不分解也不产酸;而在365nm光源下4种光生酸剂的分解及产酸量子产率均很低。     

Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors

Previous studies aimed at exploring the SAR of C2-functionalized S-DABOs demonstrated that the substituent at this position plays a key role in the inhibition of both wild-type RT and drug-resistant enzymes, particularly the K103N mutant form. The introduction of a cyclopropyl group led us to the discovery of a potent inhibitor with picomolar activity against wild-type RT and nanomolar activity against many key mutant forms such as K103N. Despite its excellent antiviral profile, this compound suffers from a suboptimal ADME profile typical of many S-DABO analogues, but it could, however, represent a promising candidate as an anti-HIV microbicide. In the present work, a new series of S-DABO/N-DABO derivatives were synthesized to obtain additional SAR information on the C2-position and in particular to improve ADME properties while maintaining a good activity profile against HIV-1 RT. In vitro ADME properties (PAMPA permeation, water solubility, and metabolic stability) were also experimentally evaluated for the most interesting compounds to obtain a reliable indication of their plasma levels after oral administration.     

含杂原子多乙烯基醚化合物的最新进展

阳离子聚合反应是UV固化技术中的重要体系,其中乙烯基醚类化合物由于聚合速度快、聚合不易受氧气干扰、低毒、无味等优点被广泛应用在涂料、黏合剂、印刷等领域,这些应用的发展推动了新的乙烯基醚类化合物的合成研究。此外,分子中含有金属或无机元素的有机物,往往具有较为特殊的性质,本文就近几年出现的含磷、硅、氮等杂原子的乙烯基醚类化合物进行了总结。     

Exploring the Antiplasmodial 2-Aminopyridines as Potential Antitrypanosomal Agents

Recently we reported the results of a screen of the Pathogen Box in which we identified 4-(2-amino-5-(4-(methylsulfonyl) phenyl) pyridin-3-yl)-2-methoxyphenol (MMV010576, 1 ) as our priority antitrypanosomal hit. This compound had previously been identified as a potent and selective antiplasmodial agent, where a focused optimization campaign, resulted in a medium-sized library of compounds, with favorable drug-like properties, one of which (MMV048, 2 , 5-(4-(methylsulfonyl)phenyl)-6′-(trifluoromethyl)-[3,3′-bipyridin]-2-amine) is currently undergoing clinical trials for malaria. Accordingly, we investigated this library, in order to elucidate structural activity relationship details of this class of compounds as inhibitors of Trypanosoma brucei. Our study has identified several structural features important for antitrypanosomal activity, which are distinct from those required for antiplasmodial activity. Results from this study can be exploited to develop potent antitrypanosomal agents.     

Processing and mechanical properties of bio‐derived vinyl ester resin‐based composites

A “green” vinyl ester resin (GVER) is investigated for use in structural applications. The GVER was formulated using a monodisperse vinyl ester created via a novel synthetic route capable of using bio‐waste material from paper and biodiesel industries. The GVER was used either as a neat resin or as blended with a commercial vinyl ester resin. The processing viscosity and gel times are investigated. The GVER reaches a similar viscosity as the commercial resin with only half the styrene monomer content, thereby reducing the volatile organic compounds associated with manufacturing. Composites of the GVER matrix reinforced by carbon fabric were tested for their tensile and flexural properties. The mechanical performance of the GVER compares favorably with commercial resin and provide a route for composites manufacturing from sustainably sourced vinyl ester matrix. © 2016 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2017 , 134, 44642.     

Structural Basis of Microtubule Stabilization by Discodermolide

Microtubule‐stabilizing agents (MSAs) are widely used in chemotherapy. Using X‐ray crystallography we elucidated the detailed binding modes of two potent MSAs, (+)‐discodermolide (DDM) and the DDM–paclitaxel hybrid KS‐1‐199‐32, in the taxane pocket of β‐tubulin. The two compounds bind in a very similar hairpin conformation, as previously observed in solution. However, they stabilize the M‐loop of β‐tubulin differently: KS‐1‐199‐32 induces an M‐loop helical conformation that is not observed for DDM. In the context of the microtubule structure, both MSAs connect the β‐tubulin helices H6 and H7 and loop S9–S10 with the M‐loop. This is similar to the structural effects elicited by epothilone A, but distinct from paclitaxel. Together, our data reveal differential binding mechanisms of DDM and KS‐1‐199‐32 on tubulin.     

噻唑/·唑类活性天然产物及活性小分子化合物研究进展

介绍了天然界中存在很多含有噻唑/(口恶)唑结构单元的活性分子,其生物合成途径或仿生合成方法通常分别以多肽氨基酸残基的羧酸基团或羧酸衍生物为底物,与半胱氨酸/丝氨酸等天然氨基酸或经过衍生化的非天然氨基酸环合、氧化而成,因此天然产物中的噻唑/(口恶)唑C5位通常以无取代的形式存在。然而,C5位二聚化、烯基化或芳基化的噻唑/(口恶)唑结构单元常见于具有广泛药理活性的人工合成的分子中,构建这类结构单元通常都需预先制备β-取代的非天然氨基酸。并且,关于该类天然产物的结构改造均未涉及噻唑/(口恶)唑C5位上的官能团化修饰,这是由于目前尚缺乏该位点上的官能团化方法而造成的。该现状预示着,开发噻唑/(口恶)唑C5位官能团化新方法,并将其应用于噻唑/(口恶)唑天然产物的结构修饰,具有十分重要的意义和研究价值。     

Structural Elaboration of a Natural Product: Identification of 3,3′‐Diindolylmethane Aminophosphonate and Urea Derivatives as Potent Anticancer Agents

An approach involving rational structural elaboration of the biologically active natural product diindolylmethane (DIM) with the incorporation of aminophosphonate and urea moieties toward the discovery of potent anticancer agents was considered. A four‐step approach for the synthesis of DIM aminophosphonate and urea derivatives was established. These novel compounds showed potent anticancer activities in two representative kidney and colon cancer cell lines, low toxicity to normal cells, higher potency than the parent natural product DIM and etoposide, and potent inhibition of cancer cell migration. Biophysical and immunological studies, including DAPI nuclear staining, western blot analysis with apoptotic protein markers, flow cytometry, immunocytochemistry, and comet assays of the two most potent compounds revealed good efficacies in apoptosis and DNA damage. It was found that down‐regulation of nuclear factor κB (NF‐κB p65) could be an important mode of action in apoptosis, and the two most potent derivatives were found to be more potent than parent compound DIM in the down‐regulation of NF‐κB. Our results show the importance of structural elaboration of DIM by rational incorporation of aminophosphonate and urea moieties to produce potent anticancer agents; they also suggest that this approach using other structurally simple bioactive natural products as scaffolds holds promise for future drug discovery and development.     

Screening,Synthesis, and In Vitro Evaluation of Vinyl Sulfones as Inhibitors of Complement‐Dependent Cytotoxicity in Neuromyelitis Optica

Neuromyelitis optica (NMO) is a demyelinating autoimmune disease of the optic nerve and spinal cord triggered by binding of NMO‐specific immunoglobulin G (NMO‐IgG) auto‐antibodies to the water channel aquaporin‐4 (AQP4) in astrocytes. To find potential NMO therapeutics, a screening system was established and used to identify inhibitors of NMO‐IgG‐mediated complement‐dependent cytotoxicity (CDC). The screening of approximately 400 compounds yielded potent hit compounds with inhibitory effects against CDC in U87‐MG cells expressing human AQP4. Derivatives of the hit compounds were synthesized and evaluated for their inhibition of CDC. Of the small molecules synthesized, (E)‐1‐(2‐((4‐methoxyphenyl)sulfonyl)vinyl)‐[4‐[(3‐trifluoromethyl)phenyl] methoxy]benzene ( 5 c ) showed the most potent activity in both stably transfected U87‐MG cells and mice‐derived astrocytes. The results of this study suggest that 5 c , which targets NMO‐IgG‐specific CDC, may be useful as a research tool and a potential candidate for therapeutic development for the treatment of NMO.     

Design,Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediate‐Early 2 Protein,a Promising Target for Anti‐HCMV Treatment

Although human cytomegalovirus (HCMV) infection is mostly asymptomatic for immunocompetent individuals, it remains a serious threat for those who are immunocompromised, in whom it is associated with various clinical manifestations. The therapeutic utility of the few available anti‐HCMV drugs is limited by several drawbacks, including cross‐resistance due to their common mechanism of action, i.e., inhibition of viral DNA polymerase. Therefore, compounds that target other essential viral events could overcome this problem. One example of this is the 6‐aminoquinolone WC5 , which acts by directly blocking the transactivation of essential viral Early genes by the Immediate‐Early 2 (IE2) protein. In this study, the quinolone scaffold of the lead compound WC5 was investigated in depth, defining more suitable substituents for each of the scaffold positions explored and identifying novel, potent and nontoxic compounds. Some compounds showed potent anti‐HCMV activity by interfering with IE2‐dependent viral E gene expression. Among them, naphthyridone 1 was also endowed with potent anti‐HIV activity in latently infected cells. Their antiviral profile along with their innovative mechanism of action make these anti‐HCMV quinolones a very promising class of compounds to be exploited for more effective antiviral therapeutic treatment.     

TG/FTIR/MS study on the influence of nanoparticles content upon the thermal decomposition of starch/poly(vinyl alcohol) montmorillonite nanocomposites

The effect of the nanoclay content on the thermal decomposition of nanocomposites based on poly(vinyl alcohol)/thermoplastic starch, as intercalated hybrids, has been established. The changes in the decomposition products distribution and their evolution have been investigated by coupled thermogravimetric analysis, Fourier transform infrared spectroscopy, and mass spectrometry. Detailed analysis of the in situ vapor phase showed that the poly(vinyl alcohol)/starch/clay nanocomposites display a completely different distribution pattern of degradation product, depending on nanoclay content. By in situ vapor phase FTIR and MS spectroscopic techniques, both decomposition compounds of the constituent polymers and some new ones, depending on the nanoparticles content, are identified. The effect of the increase in nanoparticles content consists mainly in variation of some volatile compounds evolution, such as formic acid, water, formaldehyde, propionic acid, methanol, acetic acid carbon dioxide, benzene, etc., which in the case of nanocomposites is very complex. Thus, a content of 2–4 wt% organically-modified montmorillonite hinders the decomposition of the poly(vinyl alcohol)/starch blend. Both characteristic temperature of evolution of the main compounds increases by increasing its content and evolution starting time is delayed; while the untreated nanoclay acts like a catalyst, which decreases characteristic temperatures and evolution time with increasing its content. The temperature dependence of the maximum evolution rate of various compounds on the nanoclay content is very complex as, in the case of nanocomposites, of both primary and secondary reactions and transport phenomena occur simultaneously. Generally, this behavior is related to the dispersion of nanoclays in the polymeric matrix.